The promise of nanomedicine has long been hindered by a fundamental challenge: how do you deliver a therapeutic payload precisely to a target site deep within the vascular network without causing systemic side effects? The ANGIE project proposes a radical answer — wireless magnetic steering of functionalized nanocarriers guided in real time to any region of the body.
Funded under the EU Horizon 2020 FET Proactive programme, the ANGIE consortium brings together leading research institutions across Europe to develop, validate, and translate a platform that achieves 10,000× dose reduction compared to conventional systemic drug delivery.
The core technology
At the heart of the ANGIE system is a set of magnetically responsive nanocarriers — hollow lipid-coated particles in the 100–500 nm range, loaded with a therapeutic agent and surface-functionalised with targeting ligands. These devices are injected intravenously and then guided through the bloodstream using an external rotating magnetic field generated by a custom electromagnet array.
Unlike passive targeting strategies that rely on the enhanced permeability and retention (EPR) effect, ANGIE's active steering approach works independently of tumour vascularisation and can reach virtually any anatomical location accessible by blood flow.
We are not asking the drug to find its target. We are driving it there — with the precision of a magnetic compass and the scale of a nanoparticle.
— Prof. Luca Ricotti, STLab, Scuola Superiore Sant'Anna
Steering in bifurcating vessels
One of the most technically demanding aspects of the project is navigation through vessel bifurcations — branching points where blood flow divides and passive particles would distribute stochastically. ANGIE addresses this by applying a time-varying magnetic gradient that biases particle trajectories toward the target branch.
In simulation studies presented at ICRA 2025, the team demonstrated steering efficiencies exceeding 85% in idealised bifurcating geometries, with performance degrading gracefully as vessel tortuosity increased. Physical validation in microfluidic phantom vessels confirmed the simulation predictions within experimental error.
Key findings from the bifurcation study
- 85%+ steering efficiency in symmetric Y-bifurcations at physiological flow rates
- Steering maintained across a 10-fold range of nanoparticle concentrations
- No measurable aggregation under the applied field strength
- Real-time MRI feedback enabled closed-loop trajectory correction
Open Data
All simulation datasets, microfluidic validation data, and imaging sequences from this study are available under CC-BY 4.0 in the ANGIE project repository. Raw MRI sequences are deposited at Zenodo.
Imaging and closed-loop control
Real-time MRI guidance is central to the ANGIE control architecture. The platform integrates a low-field MRI scanner (0.5T) with the electromagnet array, enabling simultaneous imaging of nanoparticle distribution and magnetic actuation without mutual interference — a significant engineering achievement given the electromagnetic environment involved.
A custom image processing pipeline extracts particle concentration maps from T2*-weighted gradient echo sequences at 4 Hz frame rate, sufficient to track the leading edge of the bolus through most vascular territories. This information feeds a model-predictive controller that adjusts the magnetic field parameters to minimise deviation from the planned trajectory.
The integration of imaging and actuation in a single instrument — that was the hardest engineering problem in this project, and solving it unlocks the entire clinical pathway.
— Dr. Arianna Menciassi, BioRobotics Institute
Towards clinical translation
The consortium is currently completing pre-clinical validation in animal models, with results expected to be reported in late 2025. A regulatory pathway analysis conducted with clinical partners identified the ANGIE platform as a combination product under EU MDR, requiring a dedicated clinical evaluation strategy that the consortium is preparing in parallel with the scientific work.
If pre-clinical results support the predicted efficacy and safety profile, a first-in-human feasibility study is planned for 2027, targeting hepatocellular carcinoma as the initial indication — a tumour type where the liver's vascular anatomy offers a favourable environment for magnetic steering.
